Birdwatch Note
2023-08-31 10:55:04 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
No es cierto que cure el cáncer en 7 minutos; eso es lo que se tarda de media en inyectar esta formulación. En España, el fármaco (Atezolizumab, autorizado en 2017) está solo indicado para ciertos tipos de tumores, y no en inyección sino en perfusión continua intravenosa. https://cima.aemps.es/cima/publico/detalle.html?nregistro=1171220001
Written by 5A674581C20E4584BC965F37F1E7780EAE72F02CE157D21ED5C44D9E4BD4A0F6
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1697169877574844583
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1697201333202301142
- noteId - 1697201333202301142
- participantId -
- noteAuthorParticipantId - 5A674581C20E4584BC965F37F1E7780EAE72F02CE157D21ED5C44D9E4BD4A0F6 Participant Details
- createdAtMillis - 1693479304970
- tweetId - 1697169877574844583
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 0
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- No es cierto que cure el cáncer en 7 minutos; eso es lo que se tarda de media en inyectar esta formulación. En España, el fármaco (Atezolizumab, autorizado en 2017) está solo indicado para ciertos tipos de tumores, y no en inyección sino en perfusión continua intravenosa. https://cima.aemps.es/cima/publico/detalle.html?nregistro=1171220001
Note Status History
| createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
| 2023-08-31 10:55:04 UTC (1693479304970) |
2023-08-31 16:10:08 UTC (1693498208087) |
CURRENTLY_RATED_HELPFUL | 2023-09-01 02:41:20 UTC (1693536080941) |
CURRENTLY_RATED_HELPFUL | 2023-08-31 16:10:08 UTC (1693498208087) |
CURRENTLY_RATED_HELPFUL |
Note Ratings
| rated at | rated by | |
| 2023-08-31 19:30:37 -0500 | Rating Details | |
| 2023-08-31 18:38:11 -0500 | Rating Details | |
| 2023-08-31 18:06:35 -0500 | Rating Details | |
| 2023-08-31 18:03:35 -0500 | Rating Details | |
| 2023-08-31 18:00:45 -0500 | Rating Details | |
| 2023-08-31 17:25:35 -0500 | Rating Details | |
| 2023-08-31 17:19:16 -0500 | Rating Details | |
| 2023-08-31 16:45:03 -0500 | Rating Details | |
| 2023-08-31 16:39:13 -0500 | Rating Details | |
| 2023-08-31 16:26:09 -0500 | Rating Details | |
| 2023-08-31 16:18:30 -0500 | Rating Details | |
| 2023-08-31 15:05:01 -0500 | Rating Details | |
| 2023-08-31 14:59:59 -0500 | Rating Details | |
| 2023-08-31 14:46:46 -0500 | Rating Details | |
| 2023-08-31 14:31:30 -0500 | Rating Details | |
| 2023-08-31 14:15:08 -0500 | Rating Details | |
| 2023-08-31 13:54:34 -0500 | Rating Details | |
| 2023-08-31 13:15:17 -0500 | Rating Details | |
| 2023-08-31 12:49:35 -0500 | Rating Details | |
| 2023-08-31 12:32:46 -0500 | Rating Details | |
| 2023-08-31 10:50:24 -0500 | Rating Details | |
| 2023-08-31 10:22:18 -0500 | Rating Details | |
| 2023-08-31 10:20:28 -0500 | Rating Details | |
| 2023-08-31 10:06:25 -0500 | Rating Details | |
| 2023-08-31 09:53:48 -0500 | Rating Details | |
| 2023-08-31 09:42:59 -0500 | Rating Details | |
| 2023-08-31 09:30:21 -0500 | Rating Details | |
| 2023-08-31 09:11:01 -0500 | Rating Details | |
| 2023-08-31 09:01:22 -0500 | Rating Details | |
| 2023-08-31 08:46:58 -0500 | Rating Details | |
| 2023-08-31 08:32:02 -0500 | Rating Details | |
| 2023-08-31 07:57:37 -0500 | Rating Details | |
| 2023-08-31 07:30:38 -0500 | Rating Details | |
| 2023-08-31 07:24:35 -0500 | Rating Details | |
| 2023-08-31 06:00:14 -0500 | Rating Details | |
| 2023-09-01 17:09:46 -0500 | Rating Details | |
| 2023-09-01 11:37:25 -0500 | Rating Details | |
| 2023-09-01 11:35:27 -0500 | Rating Details | |
| 2023-09-01 11:22:35 -0500 | Rating Details | |
| 2023-09-01 11:20:59 -0500 | Rating Details | |
| 2023-09-01 06:22:30 -0500 | Rating Details | |
| 2023-09-01 06:07:56 -0500 | Rating Details | |
| 2023-09-01 05:16:21 -0500 | Rating Details | |
| 2023-09-01 03:23:36 -0500 | Rating Details | |
| 2023-09-01 03:15:50 -0500 | Rating Details | |
| 2023-09-01 01:57:32 -0500 | Rating Details | |
| 2023-09-01 01:15:07 -0500 | Rating Details | |
| 2023-09-01 01:15:00 -0500 | Rating Details | |
| 2023-09-01 00:05:55 -0500 | Rating Details | |
| 2023-08-31 23:46:27 -0500 | Rating Details | |
| 2023-08-31 22:12:05 -0500 | Rating Details | |
| 2023-08-31 21:50:01 -0500 | Rating Details | |
| 2023-08-31 21:01:33 -0500 | Rating Details | |
| 2023-08-31 20:51:11 -0500 | Rating Details | |
| 2023-08-31 19:55:57 -0500 | Rating Details | |
| 2023-09-02 05:21:45 -0500 | Rating Details | |
| 2023-09-02 01:51:14 -0500 | Rating Details | |
| 2023-09-04 03:31:14 -0500 | Rating Details | |
| 2023-08-31 17:06:59 -0500 | Rating Details |